The hyperphosphatemic effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDPTM)

Renal handling of phosphorus and the renal response to parathyroid hormone

Robert R. Recker, Gordon S. Hassing, John R. Lau, Paul D. Saville

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

To determine the mechanism responsible for serum phosphorus elevation during therapy with disodium etidronate (ethane-1-hydroxy-1,1-diphosphonate, EHDPTM), 30 mg. per kilogram EHDPTM was administered daily, orally, in 4 divided doses to 10 adult male volunteers age 22 to 45 for 11 or 12 days. Clearances of calcium, phosphorus, and creatinine were estimated in each of 4 one hour periods on 2 different days before, and on 2 days at the end of therapy while still on the drug. Intravenous bovine parathyroid hormone (PTH) was given at the beginning of the experiment on the second day in each case. Diffusible calcium and phosphorus clearances were determined on 5 of these subjects. The response to 40 units (5 subjec or 200 units (5 subjects) bovine PTH during treatment with EHDPTM30 mg. per kilogram for 11 or 12 days was compared to the response during the control period without treatment. Urine cyclic AMP excretion was also compared in each case. EHDPTM caused a significant rise in total and diffusible serum phosphorus levels with nonsignificant differences between them. Phosphorus clearance was decreased (P <0.01) but basal phosphorous excretion was unchanged by EHDPTM therapy. The phosphaturia and urine cyclic AMP excretion in response to intravenous bovine PTH, 40 units (5 subjects) or 200 units (5 subjects) was unaltered by EHDPTM therapy. The per cent change in phosphorus clearance in response to intravenous bovine PTH was also unaltered by treatment with EHDPTM. Urine calcium excretion was decreased for 2 hours following bovine PTH injection, both with and without treatment with EHDPTM. The phosphaturic response to 200 units bovine PTH was slightly greater than the response to 40 units, however, the urinary cyclic AMP excretion in response to 200 units bovine PTH was about ten-fold higher than the response to 40 units. It was concluded that EHDPTM causes hyperphosphatemia by increasing tubular reabsorption of phosphorus without causing inhibition of parathyroid hormone action on renal tubules. It is assumed that a mechanism (s) other than PTH exists for control of renal handling of phosphorus and that EHDPTM affects it (them).

Original languageEnglish
Pages (from-to)258-266
Number of pages9
JournalThe Journal of Laboratory and Clinical Medicine
Volume81
Issue number2
StatePublished - 1973

Fingerprint

Ethane
Diphosphonates
Parathyroid Hormone
Phosphorus
Kidney
Cyclic AMP
Urine
Therapeutics
Calcium
Familial Hypophosphatemia
Etidronic Acid
Hyperphosphatemia
bovine parathyroid hormone
Serum
Volunteers
Creatinine
Injections

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

@article{a6e23543d70a420c8dc90741e996f18c,
title = "The hyperphosphatemic effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDPTM): Renal handling of phosphorus and the renal response to parathyroid hormone",
abstract = "To determine the mechanism responsible for serum phosphorus elevation during therapy with disodium etidronate (ethane-1-hydroxy-1,1-diphosphonate, EHDPTM), 30 mg. per kilogram EHDPTM was administered daily, orally, in 4 divided doses to 10 adult male volunteers age 22 to 45 for 11 or 12 days. Clearances of calcium, phosphorus, and creatinine were estimated in each of 4 one hour periods on 2 different days before, and on 2 days at the end of therapy while still on the drug. Intravenous bovine parathyroid hormone (PTH) was given at the beginning of the experiment on the second day in each case. Diffusible calcium and phosphorus clearances were determined on 5 of these subjects. The response to 40 units (5 subjec or 200 units (5 subjects) bovine PTH during treatment with EHDPTM30 mg. per kilogram for 11 or 12 days was compared to the response during the control period without treatment. Urine cyclic AMP excretion was also compared in each case. EHDPTM caused a significant rise in total and diffusible serum phosphorus levels with nonsignificant differences between them. Phosphorus clearance was decreased (P <0.01) but basal phosphorous excretion was unchanged by EHDPTM therapy. The phosphaturia and urine cyclic AMP excretion in response to intravenous bovine PTH, 40 units (5 subjects) or 200 units (5 subjects) was unaltered by EHDPTM therapy. The per cent change in phosphorus clearance in response to intravenous bovine PTH was also unaltered by treatment with EHDPTM. Urine calcium excretion was decreased for 2 hours following bovine PTH injection, both with and without treatment with EHDPTM. The phosphaturic response to 200 units bovine PTH was slightly greater than the response to 40 units, however, the urinary cyclic AMP excretion in response to 200 units bovine PTH was about ten-fold higher than the response to 40 units. It was concluded that EHDPTM causes hyperphosphatemia by increasing tubular reabsorption of phosphorus without causing inhibition of parathyroid hormone action on renal tubules. It is assumed that a mechanism (s) other than PTH exists for control of renal handling of phosphorus and that EHDPTM affects it (them).",
author = "Recker, {Robert R.} and Hassing, {Gordon S.} and Lau, {John R.} and Saville, {Paul D.}",
year = "1973",
language = "English",
volume = "81",
pages = "258--266",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - The hyperphosphatemic effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDPTM)

T2 - Renal handling of phosphorus and the renal response to parathyroid hormone

AU - Recker, Robert R.

AU - Hassing, Gordon S.

AU - Lau, John R.

AU - Saville, Paul D.

PY - 1973

Y1 - 1973

N2 - To determine the mechanism responsible for serum phosphorus elevation during therapy with disodium etidronate (ethane-1-hydroxy-1,1-diphosphonate, EHDPTM), 30 mg. per kilogram EHDPTM was administered daily, orally, in 4 divided doses to 10 adult male volunteers age 22 to 45 for 11 or 12 days. Clearances of calcium, phosphorus, and creatinine were estimated in each of 4 one hour periods on 2 different days before, and on 2 days at the end of therapy while still on the drug. Intravenous bovine parathyroid hormone (PTH) was given at the beginning of the experiment on the second day in each case. Diffusible calcium and phosphorus clearances were determined on 5 of these subjects. The response to 40 units (5 subjec or 200 units (5 subjects) bovine PTH during treatment with EHDPTM30 mg. per kilogram for 11 or 12 days was compared to the response during the control period without treatment. Urine cyclic AMP excretion was also compared in each case. EHDPTM caused a significant rise in total and diffusible serum phosphorus levels with nonsignificant differences between them. Phosphorus clearance was decreased (P <0.01) but basal phosphorous excretion was unchanged by EHDPTM therapy. The phosphaturia and urine cyclic AMP excretion in response to intravenous bovine PTH, 40 units (5 subjects) or 200 units (5 subjects) was unaltered by EHDPTM therapy. The per cent change in phosphorus clearance in response to intravenous bovine PTH was also unaltered by treatment with EHDPTM. Urine calcium excretion was decreased for 2 hours following bovine PTH injection, both with and without treatment with EHDPTM. The phosphaturic response to 200 units bovine PTH was slightly greater than the response to 40 units, however, the urinary cyclic AMP excretion in response to 200 units bovine PTH was about ten-fold higher than the response to 40 units. It was concluded that EHDPTM causes hyperphosphatemia by increasing tubular reabsorption of phosphorus without causing inhibition of parathyroid hormone action on renal tubules. It is assumed that a mechanism (s) other than PTH exists for control of renal handling of phosphorus and that EHDPTM affects it (them).

AB - To determine the mechanism responsible for serum phosphorus elevation during therapy with disodium etidronate (ethane-1-hydroxy-1,1-diphosphonate, EHDPTM), 30 mg. per kilogram EHDPTM was administered daily, orally, in 4 divided doses to 10 adult male volunteers age 22 to 45 for 11 or 12 days. Clearances of calcium, phosphorus, and creatinine were estimated in each of 4 one hour periods on 2 different days before, and on 2 days at the end of therapy while still on the drug. Intravenous bovine parathyroid hormone (PTH) was given at the beginning of the experiment on the second day in each case. Diffusible calcium and phosphorus clearances were determined on 5 of these subjects. The response to 40 units (5 subjec or 200 units (5 subjects) bovine PTH during treatment with EHDPTM30 mg. per kilogram for 11 or 12 days was compared to the response during the control period without treatment. Urine cyclic AMP excretion was also compared in each case. EHDPTM caused a significant rise in total and diffusible serum phosphorus levels with nonsignificant differences between them. Phosphorus clearance was decreased (P <0.01) but basal phosphorous excretion was unchanged by EHDPTM therapy. The phosphaturia and urine cyclic AMP excretion in response to intravenous bovine PTH, 40 units (5 subjects) or 200 units (5 subjects) was unaltered by EHDPTM therapy. The per cent change in phosphorus clearance in response to intravenous bovine PTH was also unaltered by treatment with EHDPTM. Urine calcium excretion was decreased for 2 hours following bovine PTH injection, both with and without treatment with EHDPTM. The phosphaturic response to 200 units bovine PTH was slightly greater than the response to 40 units, however, the urinary cyclic AMP excretion in response to 200 units bovine PTH was about ten-fold higher than the response to 40 units. It was concluded that EHDPTM causes hyperphosphatemia by increasing tubular reabsorption of phosphorus without causing inhibition of parathyroid hormone action on renal tubules. It is assumed that a mechanism (s) other than PTH exists for control of renal handling of phosphorus and that EHDPTM affects it (them).

UR - http://www.scopus.com/inward/record.url?scp=0015576420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015576420&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 258

EP - 266

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 2

ER -